1
|
Asif M, Qusty NF, Alghamdi S. An Overview of Various Rifampicin Analogs against Mycobacterium tuberculosis and their Drug Interactions. Med Chem 2024; 20:268-292. [PMID: 37855280 DOI: 10.2174/0115734064260853230926080134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2023] [Revised: 07/14/2023] [Accepted: 08/12/2023] [Indexed: 10/20/2023]
Abstract
The success of the TB control program is hampered by the major issue of drug-resistant tuberculosis (DR-TB). The situation has undoubtedly been made more difficult by the widespread and multidrug-resistant (XDR) strains of TB. The modification of existing anti-TB medications to produce derivatives that can function on resistant TB bacilli is one of the potential techniques to overcome drug resistance affordably and straightforwardly. In comparison to novel pharmaceuticals for drug research and progress, these may have a better half-life and greater bioavailability, be more efficient, and serve as inexpensive alternatives. Mycobacterium tuberculosis, which is drugsusceptible or drug-resistant, is effectively treated by several already prescribed medications and their derivatives. Due to this, the current review attempts to give a brief overview of the rifampicin derivatives that can overcome the parent drug's resistance and could, hence, act as useful substitutes. It has been found that one-third of the global population is affected by M. tuberculosis. The most common cause of infection-related death can range from latent TB to TB illness. Antibiotics in the rifamycin class, including rifampicin or rifampin (RIF), rifapentine (RPT), and others, have a special sterilizing effect on M. tuberculosis. We examine research focused on evaluating the safety, effectiveness, pharmacokinetics, pharmacodynamics, risk of medication interactions, and other characteristics of RIF analogs. Drug interactions are especially difficult with RIF because it must be taken every day for four months to treat latent TB infection. RIF continues to be the gold standard of treatment for drug-sensitive TB illness. RIF's safety profile is well known, and the two medicines' adverse reactions have varying degrees of frequency. The authorized once-weekly RPT regimen is insufficient, but greater dosages of either medication may reduce the amount of time needed to treat TB effectively.
Collapse
Affiliation(s)
- Mohammad Asif
- Department of Pharmaceutical Chemistry, Era College of Pharmacy, Era University, Lucknow, 226003, Uttar Pradesh, India
| | - Naeem F Qusty
- Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al‒Qura University, Makkah, 21955, Saudi Arabia
| | - Saad Alghamdi
- Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al‒Qura University, Makkah, 21955, Saudi Arabia
| |
Collapse
|
2
|
Le-Deygen IM, Mamaeva PV, Skuredina AA, Safronova AS, Belogurova NG, Kudryashova EV. Combined System for the Simultaneous Delivery of Levofloxacin and Rifampicin: Structural and Functional Properties and Antibacterial Activity. J Funct Biomater 2023; 14:381. [PMID: 37504876 PMCID: PMC10381656 DOI: 10.3390/jfb14070381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 07/18/2023] [Accepted: 07/18/2023] [Indexed: 07/29/2023] Open
Abstract
The therapy of resistant forms of tuberculosis requires the simultaneous use of several drugs, in particular, a combination of rifampicin and levofloxacin. In this paper, we aimed to design a combined system for the simultaneous delivery of these drugs for potential inhalation administration. A feature of this system is the incorporation of rifampicin into optimized liposomal vesicles capable of forming a multipoint non-covalent complex with chitosan-β-cyclodextrin conjugates. Levofloxacin is incorporated into cyclodextrin tori by forming a host-guest complex. Here, a comprehensive study of the physicochemical properties of the obtained systems was carried out and special attention was paid to the kinetics of cargo release for individual drugs and in the combined system. The release of levofloxacin in combined system is slow and is described by the Higuchi model in all cases. The release of rifampicin from liposomes during the formation of complexes with polymeric conjugates is characterized by the change of the Higuchi model to the Korsmeyer-Peppas model with the main type of diffusion against Fick's law. Microbiological studies in solid and liquid growth media a consistently high antibacterial activity of the obtained systems was shown against B. subtilis and E. coli.
Collapse
Affiliation(s)
- Irina M Le-Deygen
- Chemical Enzymology Department, Lomonosov Moscow State University, 119991 Moscow, Russia
| | - Polina V Mamaeva
- Chemical Enzymology Department, Lomonosov Moscow State University, 119991 Moscow, Russia
| | - Anna A Skuredina
- Chemical Enzymology Department, Lomonosov Moscow State University, 119991 Moscow, Russia
| | - Anastasia S Safronova
- Chemical Enzymology Department, Lomonosov Moscow State University, 119991 Moscow, Russia
| | - Natalia G Belogurova
- Chemical Enzymology Department, Lomonosov Moscow State University, 119991 Moscow, Russia
| | - Elena V Kudryashova
- Chemical Enzymology Department, Lomonosov Moscow State University, 119991 Moscow, Russia
| |
Collapse
|
3
|
Patil SG, Jadhav JS, Chavan HV, Sankpal ST. Ultrasound-Assisted Efficient Synthesis of Azomethine Derivatives of 1-Phenylimidazo[1,5-a]Pyridine. Polycycl Aromat Compd 2023. [DOI: 10.1080/10406638.2023.2180527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Affiliation(s)
- Suhas G. Patil
- Sant Rawool Maharaj Mahavidyalaya, Kudal, Ratnagiri-416520, India
| | | | - Hemant V. Chavan
- Department of Chemistry, A. S. P. College, Devrukh, Ratnagiri-415804, India
| | - Sagar T. Sankpal
- Department of Chemistry, A. S. P. College, Devrukh, Ratnagiri-415804, India
| |
Collapse
|
4
|
Shah R, Shah M, Kumar V, Verma PK. Synthesis and antimycobacterial evaluation of pyrazinamide, benzimidazole and carboxamide derivatives. J Heterocycl Chem 2022. [DOI: 10.1002/jhet.4557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Rashmi Shah
- Department of Pharmaceutical Sciences Maharshi Dayanand University Rohtak Haryana India
| | | | - Vipan Kumar
- Department of Pharmaceutical Chemistry JCDV College of Pharmacy Sirsa India
| | - Prabhakar Kumar Verma
- Department of Pharmaceutical Sciences Maharshi Dayanand University Rohtak Haryana India
| |
Collapse
|
5
|
Alghamdi S, Asif M. Pyrazinamide Analogs Designed for Rational Drug Designing Strategies against Resistant Tuberculosis. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2022. [DOI: 10.1134/s1068162022030037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
6
|
Sharma B, Kumar S, Preeti, Johansen MD, Kremer L, Kumar V. 1H-1,2,3-triazole embedded Isatin-Benzaldehyde-bis(heteronuclearhydrazones): design, synthesis, antimycobacterial, and cytotoxic evaluation. Chem Biol Drug Des 2021; 99:301-307. [PMID: 34786862 DOI: 10.1111/cbdd.13984] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 09/28/2021] [Accepted: 10/30/2021] [Indexed: 12/20/2022]
Abstract
Rapid growth of global drug-resistant tuberculosis and urgent requirement for short treatment regimens is stimulating the need for discovery of new TB drugs. In this work, we report the design, synthesis and in vitro antimycobacterial evaluation of a library of isatin-derived bis(heteronuclear hydrazones). Evaluation results revealed that the inclusion of isoniazid core into 1H-1,2,3-triazole tethered isatin-benzaldehydes improved the antimycobacterial activity on tuberculosis mc2 6230 strain and significantly reduced the cytotoxicity against Vero cells. However, the introduction of semicarbazones/thiosemicarbazones or pyrazine-2-carbohydrazide produced the opposite effects. The compounds with isoniazid and polar-donating groups at the C-5 position of isatin emerged as the most promising conjugates with MIC99 = 0.36 µg/ml. The most active compounds were non-cytotoxic to Vero cells (IC50 >100 µg/ml) with selectivity indices >277.
Collapse
Affiliation(s)
- Bharvi Sharma
- Department of Chemistry, Guru Nanak Dev University, Amritsar, India
| | - Sumit Kumar
- Department of Chemistry, Guru Nanak Dev University, Amritsar, India
| | - Preeti
- Department of Chemistry, Guru Nanak Dev University, Amritsar, India
| | - Matt D Johansen
- Centre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, Montpellier, France.,Faculty of Science, Centre for Inflammation, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia
| | - Laurent Kremer
- Centre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, Montpellier, France.,INSERM, IRIM, Montpellier, France
| | - Vipan Kumar
- Department of Chemistry, Guru Nanak Dev University, Amritsar, India
| |
Collapse
|
7
|
Thorat BR, Mali SN, Rani D, Yamgar RS. Synthesis, In silico and In vitro Analysis of Hydrazones as Potential Antituberculosis Agents. Curr Comput Aided Drug Des 2021; 17:294-306. [PMID: 32141422 DOI: 10.2174/1573409916666200302120942] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 01/20/2020] [Accepted: 02/12/2020] [Indexed: 11/22/2022]
Abstract
Tuberculosis (TB) is a major cause of mortality and illness as reported by the W.H.O in 2019. The WHO report also mentioned the fact that about 10.0 million people fell ill with tuberculosis in the year 2018. Hydrazide-hydrazones having azomethine group (-NH-N=CH-) connected with carbonyl group is reported for the number of bioactivities like anti-inflammatory, anticonvulsant, anticancer, antiviral and antiprotozoal. OBJECTIVE The objective of our current study is to design and synthesise more potent hydrazide- hydrazones, containing anti-tubercular agents. METHODS In the current study, we synthesized 10 hydrazones (3a-3j) by stirring corresponding benzohydrazides (2) with substituted aldehydes (1a-j) in ethanol as a solvent and acetic acid as a catalyst at room temperature. All synthesized compounds were characterized by various spectroscopic techniques including elemental analysis, ultraviolet-visible spectroscopy, fluorescence, fourier- transform infrared spectroscopy and nuclear magnetic resonance spectroscopy. Compounds (3a-3j) were tested for in vitro anti-TB activity using Microplate Alamar Blue Assay (MABA). RESULTS All our synthesized compounds (3a-3j) were found to be potent against Mycobacteria tuberculosis (H37RV strain) with MIC (minimum inhibitory concentrations) values of 3.125-50 μg/mL. The hydrazide CO-NH protons in (3a-j) compounds are highly deshielded and showed broad singlet at 9.520-9.168 ppm. All the compounds were found to have more intense emission in the 416 - 429 nm regions and strong absorption in the regions of 316 - 327 nm. Synthesized compounds were also tested for in silico analysis using different software for their Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) analysis. All the compounds were found to be in silico non-carcinogenic. CONCLUSION It will be worth saying that our in silico and in vitro approaches used in the current study will become a guide for medicinal chemists to make structural modifications and synthesize more effective and potent hydrazone containing anti-tubercular agents.
Collapse
Affiliation(s)
- Bapu R Thorat
- Department of Chemistry, Government of Maharashtra's Ismail Yusuf College of Arts, Science and Commerce, Mumbai 60, India
| | - Suraj N Mali
- Government College of Pharmacy, Karad, Maharashtra, 415125, India
| | - Deepa Rani
- Department of Chemistry, Government of Maharashtra's Ismail Yusuf College of Arts, Science and Commerce, Mumbai 60, India
| | - Ramesh S Yamgar
- Department of Chemistry, Chikitsak Samuha's Patkar-Varde College of Arts, Science and Commerce, Goregaon (West), Mumbai 400 062, India
| |
Collapse
|
8
|
Synthesis, characterization, toxic substructure prediction, hepatotoxicity evaluation, marine pathogenic bacteria inhibition, and DFT calculations of a new hydrazone derived from isoniazid. J Mol Struct 2020. [DOI: 10.1016/j.molstruc.2020.128817] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
9
|
|
10
|
Almeida ML, Viana DCF, da Costa VCM, Dos Santos FA, Pereira MC, Pitta MGR, de Melo Rêgo MJB, Pitta IR, Pitta MGR. Synthesis, Antitumor Activity and Molecular Docking Studies on Seven Novel Thiazacridine Derivatives. Comb Chem High Throughput Screen 2020; 23:359-368. [PMID: 32189590 DOI: 10.2174/1386207323666200319105239] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Revised: 02/06/2020] [Accepted: 02/19/2020] [Indexed: 11/22/2022]
Abstract
AIM AND OBJECTIVE In the last decades, cancer has become a major problem in public health all around the globe. Chimeric chemical structures have been established as an important trend on medicinal chemistry in the last years. Thiazacridines are hybrid molecules composed of a thiazolidine and acridine nucleus, both pharmacophores that act on important biological targets for cancer. By the fact it is a serious disease, seven new 3-acridin-9-ylmethyl-thiazolidine-2,4-dione derivatives were synthesized, characterized, analyzed by computer simulation and tested in tumor cells. In order to find out if the compounds have therapeutic potential. MATERIALS AND METHODS Seven new 3-acridin-9-ylmethyl-thiazolidine-2,4-dione derivatives were synthesized through Michael addition and Knoevenagel condensation strategies. Characterization was performed by NMR and Infrared spectroscopy techniques. Regarding biological activity, thiazacridines were tested against solid and hematopoietic tumoral cell lines, namely Jurkat (acute T-cell leukemia); HL-60 (acute promyelocytic leukemia); DU 145 (prostate cancer); MOLT-4 (acute lymphoblastic leukemia); RAJI (Burkitt's lymphoma); K562 (chronic myelogenous leukemia) and normal cells PBMC (healthy volunteers). Molecular docking analysis was also performed in order to assess major targets of these new compounds. Cell cycle and clonogenic assay were also performed. RESULTS Compound LPSF/AA-62 (9f) exhibited the most potent anticancer activity against HL-60 (IC50 3,7±1,7 μM), MOLT-4 (IC50 5,7±1,1 μM), Jurkat (IC50 18,6 μM), Du-145 (IC50 20±5 μM) and Raji (IC50 52,3±9,2 μM). While the compound LPSF/AA-57 (9b) exhibited anticancer activity against the K562 cell line (IC50 51,8±7,8 μM). Derivative LPSF/AA-62 (9f) did not interfere in the cell cycle phases of the Molt-4 lineage. However, the LPSF/AA-62 (9f) derivative significantly reduced the formation of prostate cancer cell clones. The compound LPSF/AA-62 (9f) has shown strong anchorage stability with enzymes topoisomerases 1 and 2, in particular due the presence of chlorine favored hydrogen bonds with topoisomerase 1. CONCLUSION The 3-(acridin-9-ylmethyl)-5-((10-chloroanthracen-9-yl)methylene)thiazolidine-2,4-dione (LPSF/AA-62) presented the most promising results, showing anti-tumor activity in 5 of the 6 cell types tested, especially inhibiting the formation of colonies of prostate tumor cells (DU-145).
Collapse
Affiliation(s)
- Marcel L Almeida
- Laboratory of Design and Drug Synthesis (LPSF), Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife, Brazil
| | - Douglas C F Viana
- Laboratory of Design and Drug Synthesis (LPSF), Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife, Brazil
| | - Valécia C M da Costa
- Laboratory of Immunomodulation and New Therapeutic Approaches (LINAT), Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife, Brazil
| | - Flaviana A Dos Santos
- Laboratory of Immunomodulation and New Therapeutic Approaches (LINAT), Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife, Brazil
| | - Michelly C Pereira
- Laboratory of Immunomodulation and New Therapeutic Approaches (LINAT), Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife, Brazil
| | - Maira G R Pitta
- Laboratory of Immunomodulation and New Therapeutic Approaches (LINAT), Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife, Brazil
| | - Moacyr J B de Melo Rêgo
- Laboratory of Immunomodulation and New Therapeutic Approaches (LINAT), Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife, Brazil
| | - Ivan R Pitta
- Laboratory of Design and Drug Synthesis (LPSF), Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife, Brazil
| | - Marina G R Pitta
- Laboratory of Design and Drug Synthesis (LPSF), Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife, Brazil
| |
Collapse
|
11
|
Novel pyrazine based anti-tubercular agents: Design, synthesis, biological evaluation and in silico studies. Bioorg Chem 2020; 96:103610. [DOI: 10.1016/j.bioorg.2020.103610] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2019] [Revised: 12/02/2019] [Accepted: 01/20/2020] [Indexed: 12/31/2022]
|
12
|
Wang A, Lv K, Tao Z, Gu J, Fu L, Liu M, Wan B, Franzblau SG, Ma C, Ma X, Han B, Wang A, Xu S, Lu Y. Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents. Eur J Med Chem 2019; 181:111595. [DOI: 10.1016/j.ejmech.2019.111595] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Revised: 08/04/2019] [Accepted: 08/05/2019] [Indexed: 11/30/2022]
|
13
|
Lv K, Wang A, Tao Z, Fu L, Liu H, Wang B, Ma C, Wang H, Ma X, Han B, Wang A, Zhang K, Liu M, Lu Y. hERG optimizations of IMB1603, discovery of alternative benzothiazinones as new antitubercular agents. Eur J Med Chem 2019; 179:208-217. [DOI: 10.1016/j.ejmech.2019.06.053] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2019] [Revised: 05/23/2019] [Accepted: 06/18/2019] [Indexed: 02/04/2023]
|
14
|
Wang A, Lv K, Li L, Liu H, Tao Z, Wang B, Liu M, Ma C, Ma X, Han B, Wang A, Lu Y. Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents. Eur J Med Chem 2019; 178:715-725. [DOI: 10.1016/j.ejmech.2019.06.038] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Revised: 06/13/2019] [Accepted: 06/13/2019] [Indexed: 11/16/2022]
|
15
|
Mokhnache K, Karbab A, Charef N, Arrar L, Mubarak MS. Synthesis, characterization, superoxide anion scavenging evaluation, skin sensitization predictions, and DFT calculations for a new isonicotinylhydrazide analog. J Mol Struct 2019. [DOI: 10.1016/j.molstruc.2018.11.052] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
16
|
Wang A, Wang H, Geng Y, Fu L, Gu J, Wang B, Lv K, Liu M, Tao Z, Ma C, Lu Y. Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties. Bioorg Med Chem 2019; 27:813-821. [DOI: 10.1016/j.bmc.2019.01.022] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 01/18/2019] [Accepted: 01/22/2019] [Indexed: 11/24/2022]
|
17
|
Li L, Lv K, Yang Y, Sun J, Tao Z, Wang A, Wang B, Wang H, Geng Y, Liu M, Guo H, Lu Y. Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents. ACS Med Chem Lett 2018; 9:741-745. [PMID: 30034611 DOI: 10.1021/acsmedchemlett.8b00177] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2018] [Accepted: 06/26/2018] [Indexed: 12/31/2022] Open
Abstract
A series of benzamide scaffolds were designed and synthesized by the thiazinone ring opening of PBTZ169, and N-benzyl 3,5-dinitrobenzamides were finally identified as anti-TB agents in this work. 3,5-Dinitrobenzamides D5, 6, 7, and 12 exhibit excellent in vitro activity against the drug susceptive Mycobacterium tuberculosis H37Rv strain (MIC: 0.0625 μg/mL) and two clinically isolated multidrug-resistant strains (MIC < 0.016-0.125 μg/mL). Compound D6 displays acceptable safety and better pharmacokinetic profiles than PBTZ169, suggesting its promising potential to be a lead compound for future antitubercular drug discovery.
Collapse
Affiliation(s)
- Linhu Li
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- Limin Chemical Co., Ltd., Xinyi 221422, China
| | - Kai Lv
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Yupeng Yang
- Department of Stomatology, Hebei General Hospital, Shijiazhuang 050051, China
| | | | - Zeyu Tao
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Apeng Wang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Bin Wang
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
| | - Hongjian Wang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Yunhe Geng
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Mingliang Liu
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Huiyuan Guo
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Yu Lu
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
| |
Collapse
|
18
|
Synthesis and evaluation of nitrofuranyl methyl N-heterocycles derivatives as novel antitubercular agents. Future Med Chem 2018; 10:2059-2068. [PMID: 29992836 DOI: 10.4155/fmc-2018-0112] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
AIM Tuberculosis (TB) is one of the world's deadliest chronic infectious diseases caused mainly by Mycobacterium tuberculosis (MTB). Many nitrofuran derivatives were found to possess promising anti-TB potential and have been widely studied. In our previous study, we discovered diazaspiro-nitrofuran IMB1701-1702 as potent anti-TB agents. METHODOLOGY We report herein a series of nitrofuranyl methyl N-heterocycles based on IMB1701-1702. Results reveal that most of them show potent activity (minimum inhibitory concentration: <0.016-0.062 μg/ml) against MTB H37Rv strain. Especially, compound 7h without cytotoxicity, has the same minimum inhibitory concentration value of ≤0.016 μg/ml as PBTZ169 against both MTB H37Rv strain and two clinically isolated multidrug-resistant MTB strains. CONCLUSION The newly designed compound 7h might be a promising anti-TB candidate.
Collapse
|
19
|
Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety. Eur J Med Chem 2018; 151:1-8. [DOI: 10.1016/j.ejmech.2018.03.060] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Revised: 02/27/2018] [Accepted: 03/20/2018] [Indexed: 11/22/2022]
|
20
|
Unissa AN, Doss C. GP, Kumar T, Swathi S, Lakshmi AR, Hanna LE. Analysis of interactions of clinical mutants of catalase-peroxidase (KatG) responsible for isoniazid resistance in Mycobacterium tuberculosis with derivatives of isoniazid. J Glob Antimicrob Resist 2017; 11:57-67. [DOI: 10.1016/j.jgar.2017.06.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2016] [Revised: 06/18/2017] [Accepted: 06/29/2017] [Indexed: 11/17/2022] Open
|
21
|
Manning TJ, Wilkerson K, Holder T, Bartley AC, Jackson C, Plummer S, Phillips D, Krajewski L, Wylie G. Pharmacokinetic studies of a three-component complex that repurposes the front line antibiotic isoniazid against Mycobacterium tuberculosis. Tuberculosis (Edinb) 2017; 107:149-155. [PMID: 29050764 DOI: 10.1016/j.tube.2017.08.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Revised: 08/23/2017] [Accepted: 08/30/2017] [Indexed: 12/15/2022]
Abstract
The frontline tuberculosis (Tb) antibiotic isoniazid has been repurposed using a three component complex aimed at increasing the delivery efficiency and adding new avenues to its mechanism of action. This study focuses on pharmacokinetic studies of the isoniazid-sucrose-copper (II)-PEG-3350 complex. The assays include the Plasma Protein Binding Assay (85.8%), Caco-2 Permeability Assay (B→APapp, 0.13 × 10-6 cm/s), Cytochrome P450 Inhibition Assay (i.e. CYP2B6, IC50 = 7.26 μM), In vitro microsomal Stability Assay (t1/2 NADPH-Dependent > 240 min), and HepG2 Cytotoxicity (no toxicity). The National Cancer Institute's 60 cell line panel is used to measure activity against cancer cells. The percent growth values averaged over all 60 cell lines indicates the complex has no anti-cancer activity, which also suggests a lack of general toxicity. It also provides data for the complexes specificity against Mycobacterium tuberculosis.
Collapse
Affiliation(s)
- Thomas J Manning
- Chemistry Department, Valdosta State University, Valdosta, GA 31698, USA.
| | - Kyle Wilkerson
- Chemistry Department, Valdosta State University, Valdosta, GA 31698, USA
| | - Taylor Holder
- Chemistry Department, Valdosta State University, Valdosta, GA 31698, USA
| | | | - Chelsea Jackson
- Chemistry Department, Valdosta State University, Valdosta, GA 31698, USA
| | - Sydney Plummer
- Chemistry Department, Valdosta State University, Valdosta, GA 31698, USA
| | - Dennis Phillips
- PAMS Facility, Chemistry, University of Georgia, Athens, GA, USA
| | - Logan Krajewski
- Fourier Transform Ion Cyclotron Resonance (FT-ICR) Facility, National High Field Magnet Lab, Tallahassee, FL, USA
| | - Greg Wylie
- NMR Lab, Chemistry Department, Texas A&M University, College Station, TX, USA
| |
Collapse
|
22
|
Design, synthesis and antimycobacterial activity of novel imidazo[1,2- a ]pyridine-3-carboxamide derivatives. Eur J Med Chem 2017; 137:117-125. [DOI: 10.1016/j.ejmech.2017.05.044] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Revised: 05/15/2017] [Accepted: 05/20/2017] [Indexed: 11/20/2022]
|
23
|
Nusrath Unissa A, Hanna LE. Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era. Tuberculosis (Edinb) 2017; 105:96-107. [DOI: 10.1016/j.tube.2017.04.008] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 04/02/2017] [Accepted: 04/20/2017] [Indexed: 12/11/2022]
|
24
|
Lv K, You X, Wang B, Wei Z, Chai Y, Wang B, Wang A, Huang G, Liu M, Lu Y. Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents. ACS Med Chem Lett 2017. [PMID: 28626525 DOI: 10.1021/acsmedchemlett.7b00106] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
A series of new 8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one(BTZ) derivatives containing a C-2 nitrogen spiro-heterocycle moiety based on the structures of BTZ candidates BTZ043 and PBTZ169 were designed and synthesized as new antitubercular agents. Many of them were found to have excellent in vitro activity (MIC < 0.15 μM) against the drug susceptive Mycobacterium tuberculosis H37Rv strain and two clinically isolated multidrug-resistant strains. Compounds 11l and 11m display acceptable safety, greater aqueous solubility, and better pharmacokinetic profiles than PBTZ169, suggesting their promising potential to be lead compounds for future antitubercular drug discovery.
Collapse
Affiliation(s)
- Kai Lv
- Institute
of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Xuefu You
- Institute
of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Bin Wang
- Beijing
Key Laboratory of Drug Resistance Tuberculosis Research, Department
of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research
Institute, Beijing ChestHospital, Capital Medical University, Beijing 101149, China
| | - Zengquan Wei
- Tianjin Chase Sun Pharmaceutical Co. Ltd., Tianjin 301700, China
| | - Yun Chai
- Institute
of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Bo Wang
- Institute
of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Apeng Wang
- Institute
of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Guocheng Huang
- Institute
of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Mingliang Liu
- Institute
of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
| | - Yu Lu
- Beijing
Key Laboratory of Drug Resistance Tuberculosis Research, Department
of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research
Institute, Beijing ChestHospital, Capital Medical University, Beijing 101149, China
| |
Collapse
|
25
|
Ranjith P, Al-Abdullah ES, Al-Omary FA, El-Emam AA, Anto P, Sheena MY, Armaković S, Armaković SJ, Zitko J, Dolezal M, Van Alsenoy C. FT-IR and FT-Raman characterization and investigation of reactive properties of N-(3-iodo-4-methylphenyl)pyrazine-2-carboxamide by molecular dynamics simulations and DFT calculations. J Mol Struct 2017. [DOI: 10.1016/j.molstruc.2017.01.079] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
26
|
Zhang R, Lv K, Wang B, Li L, Wang B, Liu M, Guo H, Wang A, Lu Y. Design, synthesis and antitubercular evaluation of benzothiazinones containing an oximido or amino nitrogen heterocycle moiety. RSC Adv 2017. [DOI: 10.1039/c6ra25712g] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A series of 8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-ones (BTZs) bearing an oximido or amino nitrogen heterocycle moiety through modifications at the C-2 position of BTZ043 and BPTZ169 were designed and synthesized as new antitubercular agents.
Collapse
Affiliation(s)
- Rui Zhang
- Institute of Medicinal Biotechnology
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- Beijing 100050
- China
| | - Kai Lv
- Institute of Medicinal Biotechnology
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- Beijing 100050
- China
| | - Bin Wang
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research
- Department of Pharmacology
- Beijing Tuberculosis and Thoracic Tumor Research Institute
- Beijing Chest Hospital
- Capital Medical University
| | - Linhu Li
- Institute of Medicinal Biotechnology
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- Beijing 100050
- China
| | - Bo Wang
- Institute of Medicinal Biotechnology
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- Beijing 100050
- China
| | - Mingliang Liu
- Institute of Medicinal Biotechnology
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- Beijing 100050
- China
| | - Huiyuan Guo
- Institute of Medicinal Biotechnology
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- Beijing 100050
- China
| | - Apeng Wang
- Institute of Medicinal Biotechnology
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- Beijing 100050
- China
| | - Yu Lu
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research
- Department of Pharmacology
- Beijing Tuberculosis and Thoracic Tumor Research Institute
- Beijing Chest Hospital
- Capital Medical University
| |
Collapse
|
27
|
Hydrazide-hydrazones as potential antimicrobial agents: overview of the literature since 2010. Med Chem Res 2016; 26:287-301. [PMID: 28163562 PMCID: PMC5250660 DOI: 10.1007/s00044-016-1756-y] [Citation(s) in RCA: 135] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Accepted: 11/17/2016] [Indexed: 10/25/2022]
Abstract
Hydrazide-hydrazone derivatives are present in many bioactive molecules and display a wide variety of biological activities, such as antibacterial, antitubercular, antifungal, anticancer, anti-inflammatory, anticonvulsant, antiviral, and antiprotozoal action. Therefore, many medicinal chemists synthesize various hydrazide-hydrazones and evaluate them for biological activities. Among biological properties of this class of compounds, antimicrobial activity is the most frequently encountered in scientific literature. This paper is focused on the overview of the literature findings of the last six years (2010-2016) covering the research on antimicrobial activity of hydrazide-hydrazone derivatives. This review may also serve as a useful guide for the development of new hydrazide-hydrazones as potential antimicrobial agents.
Collapse
|
28
|
Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. INFECTION GENETICS AND EVOLUTION 2016; 45:474-492. [DOI: 10.1016/j.meegid.2016.09.004] [Citation(s) in RCA: 118] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Revised: 09/02/2016] [Accepted: 09/03/2016] [Indexed: 12/17/2022]
|
29
|
Popiołek Ł, Biernasiuk A. Design, synthesis, and in vitro antimicrobial activity of hydrazide-hydrazones of 2-substituted acetic acid. Chem Biol Drug Des 2016; 88:873-883. [PMID: 27422854 DOI: 10.1111/cbdd.12820] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Revised: 07/06/2016] [Accepted: 07/09/2016] [Indexed: 11/29/2022]
Abstract
In this study, 30 hydrazide-hydrazones of phenylacetic (3-10) and hydroxyacetic acid (11-32) were synthesized by the condensation reaction of appropriate 2-substituted acetic acid hydrazide with different aromatic aldehydes. The obtained compounds were characterized by spectral data and evaluated in vitro for their potential antimicrobial activities against a panel of reference strains of micro-organisms, including Gram-positive bacteria, Gram-negative bacteria, and fungi belonging to the Candida spp. The results from our antimicrobial assays indicated that among synthesized compounds 3-32, especially compounds 6, 14, and 26 showed high bactericidal activity (MIC = 0.488-7.81 μg/ml) against reference Gram-positive bacteria, and in some cases, their activity was even better than that of commonly used antibiotics, such as cefuroxime or ampicillin.
Collapse
Affiliation(s)
- Łukasz Popiołek
- Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Lublin, Poland.
| | - Anna Biernasiuk
- Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Medical University of Lublin, Lublin, Poland
| |
Collapse
|
30
|
Nusrath Unissa A, Hassan S, Indira Kumari V, Revathy R, Hanna LE. Insights into RpoB clinical mutants in mediating rifampicin resistance in Mycobacterium tuberculosis. J Mol Graph Model 2016; 67:20-32. [DOI: 10.1016/j.jmgm.2016.04.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2015] [Revised: 03/25/2016] [Accepted: 04/18/2016] [Indexed: 11/29/2022]
|